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Aim
Many studies reported in HIV-positive patients 50% of
hepatitis B vaccine response with a duration of protection
between 24 and 36 months. The aim of our study is to
determine the long term protection in our HIV patients
who responded to a standard immunization schedule.
Materials and methods
Our database NADIS allows us to collect information
from March 1986 to October 2013 (gender, age, CD4
count, HIVRNA and Hepatitis B surface antibody titers =
HBs Ab > 10 IU / L.)
Patients were included gradually after 3 Engerix B 20
hepatitis B vaccines at day 1, one month and 6 months
later, conferring a rate of HBs ab > 10 IU /L. Then we
observed the duration of protection from the initial
response.
Results
Among 403 HIV patients who responded to HBV, 298
were men (74%) vs 105 women (26%). The median age
was 36 years. We observed a progressive decline in HBs
ab titer until <10 IU/ L. At 24 months 74.7% (n=223) men
remained protected vs 79.2% (n=83) women. At
60 months. 33.1% (n=99) men lost their HB protection vs
27.7% (n=29) women (LR = 0,11 NS).
At 84 months and over 120 months, 34.7% (n=103)
and 39.1% (n=117) men lost their HB protection vs
35.8% (n=38) and 38.2% women (n=40).
Conclusions
Long term HBV protection was observed in the majority
of our HIV patients. One third had lost their HBs ab
after 2 years, and require HB boost injections. We are
thinking of using an adjuvanted HB vaccine as a booster
to provide a sustained protection. We will also study
factors associated with the loss of HBV protection.
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